DDInter853 DDInter927
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Haloperidol {u} (Compound) resembles {v} (Compound) Bepotastine
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Haloperidol {u} (Compound) resembles {v} (Compound) Sertindole
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Haloperidol {u} (Compound) binds {v} (Gene) CYP2C9
Haloperidol {u} (Compound) palliates {v} (Disease) schizophrenia
Haloperidol {u} (Compound) downregulates {v} (Gene) CDC20
Haloperidol {u} (Compound) causes {v} (Side Effect) Extrapyramidal disorder
Haloperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Haloperidol {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Haloperidol (Compound) resembles Bepotastine (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Haloperidol (Compound) resembles Sertindole (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Haloperidol (Compound) binds CYP2C9 (Gene)
Haloperidol (Compound) palliates schizophrenia (Disease)
Haloperidol (Compound) downregulates CDC20 (Gene)
Haloperidol (Compound) causes Extrapyramidal disorder (Side Effect)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Haloperidol may lead to a major life threatening interaction when taken with Anagrelide